Olvimulogene nanivacirepvec
- Generic Name
- Olvimulogene nanivacirepvec
- Drug Type
- Biotech
- CAS Number
- 1473430-36-2
- Unique Ingredient Identifier
- CF19SF72O5
- Background
Olvimulogene nanivacirepvec is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
- Conditions
- Advanced Non-squamous Non-small-cell Lung CancerAdvanced Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung Cancer RecurrentMetastatic Non-squamous Non Small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-small Cell Lung CancerNon-small Cell Lung Cancer Stage IVNon-small Cell Lung Cancer Stage III
- Interventions
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 142
- Registration Number
- NCT06463665
- Locations
- 🇺🇸
Gabrail Cancer and Research Center, Canton, Ohio, United States
🇺🇸Clermont Oncology Center, Clermont, Florida, United States
🇺🇸University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
- Conditions
- Platinum-resistant Ovarian CancerPlatinum-refractory Ovarian CancerPrimary Peritoneal CancerFallopian Tube CancerEndometrioid Ovarian CancerHigh-grade Serous Ovarian CancerOvarian Clear Cell Carcinoma
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Genelux Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05281471
- Locations
- 🇺🇸
The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope, Duarte, California, United States
Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care
- Conditions
- Advanced Stage Cancer (Solid Tumor Disease for 4 Patients)Acute Myeloid Leukemia (6 Patients)
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Genelux Corporation
- Registration Number
- NCT03420430
- Locations
- 🇺🇸
Florida Hospital Cancer Institute, Orlando, Florida, United States
Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma
- First Posted Date
- 2013-01-11
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT01766739
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis
- Conditions
- Peritoneal Carcinomatosis
- First Posted Date
- 2011-09-29
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genelux GmbH
- Target Recruit Count
- 9
- Registration Number
- NCT01443260
- Locations
- 🇩🇪
University Hospital Tuebingen, Tuebingen, Germany
Safety Study of GL-ONC1, an Oncolytic Virus, in Patients With Advanced Solid Tumors
- Conditions
- Advanced Cancers (Solid Tumors)
- First Posted Date
- 2008-11-19
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- Genelux GmbH
- Target Recruit Count
- 43
- Registration Number
- NCT00794131
- Locations
- 🇬🇧
Royal Marsden Hospital, Surrey, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.